Silexion Therapeutics completes key study on SIL-204 in pancreatic cancer models, initial results expected soon
Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA interference therapy, has reached a major milestone with the completion of its initial study ... Read More
Silexion Therapeutics’ SIL-204 shows potential to transform pancreatic cancer treatment
Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company specializing in RNA interference (RNAi) therapies, has reported promising preclinical results for its next-generation therapeutic candidate, ... Read More
Silexion Therapeutics’ SIL-204 shows promise in transforming pancreatic cancer treatment
Silexion Therapeutics, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies, has released compelling preclinical data for its second-generation siRNA candidate, SIL-204. The findings reveal ... Read More